No headlines found.
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2025
Globe Newswire (Thu, 6-Nov 4:01 PM ET)
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
Siga Technologies trades on the NASDAQ stock market under the symbol SIGA.
As of February 4, 2026, SIGA stock price declined to $6.73 with 362,041 million shares trading.
SIGA has a beta of 1.35, meaning it tends to be more sensitive to market movements. SIGA has a correlation of 0.19 to the broad based SPY ETF.
SIGA has a market cap of $480.80 million. This is considered a Small Cap stock.
In the last 3 years, SIGA traded as high as $12.83 and as low as $4.22.
The top ETF exchange traded funds that SIGA belongs to (by Net Assets): VTI, AVUV, IWM, VXF, DFAT.
SIGA has outperformed the market in the last year with a price return of +26.8% while the SPY ETF gained +16.0%. However, in the short term, SIGA had mixed performance relative to the market. It has underperformed in the last 3 months, returning -17.9% vs +0.7% return in SPY. But in the last 2 weeks, SIGA shares have fared better than the market returning +2.9% compared to SPY +1.3%.
SIGA support price is $6.80 and resistance is $7.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SIGA shares will trade within this expected range on the day.
